EU/3/10/779: Orphan designation for the treatment of familial adenomatous polyposis (FAP)



On 20 September 2010, orphan designation (EU/3/10/779) was granted by the European Commission to Cancer Prevention Pharma Ltd, United Kingdom, for eflornithine for the treatment of familial adenomatous polyposis.

The sponsorship was transferred to Cancer Prevention Pharma (Ireland) Limited. Ireland, in April 2019.

Key facts

Active substance
Intended use
Treatment of familial adenomatous polyposis (FAP)
Orphan designation status
EU designation number
Date of designation

Cancer Prevention Pharma (Ireland) Limited
70 Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Tel. +353 1 232 2000

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating